Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...
Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...
Hosted on MSN19h
Company News for Mar 3, 2025The AES Corp.’s (AES) shares jumped 11.7% after the company reported fourth-quarter 2024 adjusted earnings per share of $0.54, surpassing the Zacks Consensus Estimate of $0.34. Shares of Recursion ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Certara (CERT – Research Report), Lantheus ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...
Investors are ramping up AI-related M&A to secure cutting-edge capabilities and market-beating returns, but high valuations and open-source ...
The "Enterprise Tech Ecosystem Series: F. Hoffmann - La Roche Ltd 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into company's tech activities, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback